5 Best Healthcare Market Research Firms in Kuwait (2026)

Kuwait is a high-income GCC market with one of the highest per-capita healthcare expenditures in the region. The Kuwait pharmaceutical market is valued at approximately $1.5 billion and growing at 5–7% annually, driven by rising chronic disease burden — Kuwait has one of the world's highest diabetes rates, affecting approximately 25% of adults — increasing healthcare privatisation, and growing pharmaceutical innovation adoption.

Healthcare market research in Kuwait is shaped by three defining characteristics:

• MOH-dominated healthcare system: Kuwait's Ministry of Health operates the majority of the country's hospitals, polyclinics, and pharmacies, providing free healthcare to all Kuwaiti nationals. The MOH central formulary controls pharmaceutical access across government facilities — research must understand MOH registration timelines, formulary committee processes, and the role of specialist physicians in MOH academic hospitals as primary prescribing influencers.
• Kuwait Drug Committee (KDC) gatekeeper: The KDC evaluates and approves products for the national formulary — the essential pathway for pharmaceutical market access in Kuwait. KDC submissions require robust clinical and health economic evidence. Research firms with KDC-aware evidence generation capability add direct commercial value to pharmaceutical clients' market access strategies.
• Compact but influential HCP market: Kuwait's specialist physician community is small by global standards but highly concentrated in Kuwait City government hospitals and increasingly in private facilities. Key opinion leaders in specialties such as oncology, cardiology, and nephrology carry disproportionate influence — making KOL-focused research strategy essential.

For pharmaceutical companies, consumer health brands, and medical device firms, the right healthcare market research partner for Kuwait must combine global research rigour with in-country MOH and KDC knowledge, Arabic-English bilingual capability, and access to Kuwait's concentrated government hospital HCP network.

For additional Kuwait market context, see our Kuwait market access research guide and GCC pharmaceutical market research overview.

Kuwait's specialist physician community is relatively small and concentrated, primarily in Kuwait City government hospitals. Key academic and tertiary centres include: Mubarak Al-Kabeer Hospital (the primary tertiary referral and teaching hospital), Kuwait Cancer Control Center (KCCC) (the principal oncology centre and KOL hub for cancer therapy areas), Al-Amiri Hospital and Al-Sabah Hospital (general medicine and specialty centres). Private hospitals, led by Al-Salam, Royale Hayat, and Hadi Hospital, are growing but represent a smaller share of specialist activity.

For pharmaceutical companies, KOL mapping in Kuwait identifies physicians with high prescribing influence, publication activity, and institutional authority in oncology, cardiovascular, diabetes, nephrology, and other specialty areas. Kuwait KOLs often hold regional influence through GCC conference participation, advisory board membership (particularly in oncology), and cross-border referral relationships with Saudi and UAE colleagues.

HCP surveys in Kuwait require verified recruitment from MOH hospital rosters and private facility networks. Due to Kuwait's small but highly educated specialist community, qualitative depth interviews with key opinion leaders, hospital pharmacists, and KDC committee members often provide more actionable intelligence than large quantitative surveys alone.

BioNixus conducts KOL mapping and HCP research in Kuwait across oncology, cardiovascular, diabetes, nephrology, immunology, and other specialty areas — with verified government hospital recruitment and Arabic-English bilingual instruments. See our Kuwait market access research guide and GCC pharmaceutical market research overview for methodology details.